Author

Stephen L. Becker

Observed names: Stephen Becker, Stephen L Becker

Observed institutions: University of Southern California, San Francisco General Hospital, National Institutes of Health, Gates Foundation, Harvard University, Johns Hopkins University, University of California, San Francisco, University of Washington, California Pacific Medical Center, Harborview Medical Center, Social and Scientific Systems (United States), National Institute of Allergy and Infectious Diseases, Chelsea and Westminster Hospital, Gilead Sciences (United States)

OpenAlex ID: A5105420569

Tenofovir Disoproxil Fumarate in Nucleoside-Resistant HIV-1 Infection

2003 · Kathleen Squires, Anton L. Pozniak, et al. · Annals of Internal Medicine · 200

Multiple-Dose Escalation Study of the Safety, Pharmacokinetics, and Biologic Activity of Oral AMD070, a Selective CXCR4 Receptor Inhibitor, in Human Subjects

2007 · Nimalie D. Stone, Shelia B. Dunaway, et al. · Antimicrobial Agents and Chemotherapy · 133

HIV‐Associated Thrombotic Microangiopathy in the Era of Highly Active Antiretroviral Therapy: An Observational Study

2004 · Stephen Becker, Gregory Fusco, et al. · Clinical Infectious Diseases · 108

Proof of Activity with AMD11070, an Orally Bioavailable Inhibitor of CXCR4‐Tropic HIV Type 1

2009 · Graeme Moyle, Edwin DeJesus, et al. · Clinical Infectious Diseases · 80

A Controlled Phase Ii Trial Assessing Three Doses of Enfuvirtide (T-20) in Combination with Abacavir, Amprenavir, Ritonavir and Efavirenz in Non-Nucleoside Reverse Transcriptase Inhibitor-Naive HIV-Infected Adults

2003 · Jacob P Lalezari, Edwin DeJesus, et al. · Antiviral Therapy · 78

PDF

Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection

2000 · Joseph J. Eron, Ellen S. Yetzer, et al. · AIDS · 61

Anaphylactoid Drug Reactions to Ciprofloxacin and Rifampicin in Hiv-infected Patients

1989 · RebeccaM. Wurtz, Donald Abrams, et al. · The Lancet · 58

Young HIV-infected adults are at greater risk for medication nonadherence.

2002 · Stephen L Becker, Christopher M Dezii, et al. · PubMed · 53

Clinical and Economic Outcomes of Nonadherence to Highly Active Antiretroviral Therapy in Patients With Human Immunodeficiency Virus

2006 · Julie Munakata, Joshua S. Benner, et al. · Medical Care · 46

Liver Toxicity in Epidemiological Cohorts

2004 · Stephen Becker · Clinical Infectious Diseases · 46

Planning for pre‐exposure prophylaxis to prevent HIV transmission: challenges and opportunities

2010 · Susan C Kim, Stephen Becker, et al. · Journal of the International AIDS Society · 45

PDF

New Approaches to Antiretroviral Drug Delivery: Challenges and Opportunities Associated with the Use of Long-Acting Injectable Agents

2013 · Marta Boffito, Akil Jackson, et al. · Drugs · 42

Thymidine Analog and Multinucleoside Resistance Mutations Are Associated with Decreased Phenotypic Susceptibility to Stavudine in HIV Type 1 Isolated from Zidovudine-Naive Patients Experiencing Viremia on Stavudine-Containing Regimens

2001 · Lisa Ross, Anthony Scarsella, et al. · AIDS Research and Human Retroviruses · 33

Pharmacokinetics and Pharmacodynamics in HIV Prevention; Current Status and Future Directions: A Summary of the DAIDS and BMGF Sponsored Think Tank on Pharmacokinetics (PK)/Pharmacodynamics (PD) in HIV Prevention

2013 · Joseph Romano, Angela Kashuba, et al. · AIDS Research and Human Retroviruses · 30

CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related.

2004 · Thomas N Kakuda, Peter L Anderson, et al. · PubMed · 28

Zidovudine and Stavudine Sequencing in HIV Treatment Planning: Findings From the CHORUS HIV Cohort

2001 · Stephen L. Becker, Stephen R. Raffanti, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 28

Pharmacokinetic Effect of AMD070, an Oral CXCR4 Antagonist, on CYP3A4 and CYP2D6 Substrates Midazolam and Dextromethorphan in Healthy Volunteers

2008 · Myaing M Nyunt, Stephen Becker, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 25

Effect of Low-Dose Ritonavir on the Pharmacokinetics of the CXCR4 Antagonist AMD070 in Healthy Volunteers

2008 · Ying Jun Cao, Charles W. Flexner, et al. · Antimicrobial Agents and Chemotherapy · 24

Fosamprenavir: advancing HIV protease inhibitor treatment options

2004 · Stephen Becker, Lorna Thornton · Expert Opinion on Pharmacotherapy · 23

Treatment as prevention

2012 · Geoffrey P. Garnett, Stephen Becker, et al. · Current Opinion in HIV and AIDS · 22

Implications of HIV PrEP Trials Results

2010 · Fulvia Veronese, Peter Anton, et al. · AIDS Research and Human Retroviruses · 21

The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy

2003 · Stephen L Becker · Expert Opinion on Investigational Drugs · 21

Human Immunodeficiency Virus Type 1 Vpu Inhibitor, BIT225, in Combination with 3-Drug Antiretroviral Therapy: Inflammation and Immune Cell Modulation

2020 · Carolyn A Luscombe, Anchalee Avihingsanon, et al. · The Journal of Infectious Diseases · 19

Atazanavir: improving the HIV protease inhibitor class

2003 · Stephen Becker · Expert Review of Anti-infective Therapy · 18

Pharmacokinetic Parameters of Protease Inhibitors and the Cmin/IC50 Ratio: Call for Consensus

2001 · Stephen Becker, Alvan Fisher, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 18

Works count: 41

Citation count: 1,351

H-index: 21

I10-index: 29